Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Zai Lab Ltd ( (HK:9688) ).
Zai Lab Limited announced its unaudited financial results for Q3 2025, highlighting a 14% year-over-year revenue growth to $116.1 million and a significant reduction in operating loss. The company is advancing its global pipeline with promising developments in oncology and schizophrenia treatments, including the initiation of a global registrational study for zoci and preparations for the launch of KarXT in China. These efforts underscore Zai Lab’s commitment to expanding its market presence and delivering long-term value to shareholders.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on innovative therapies for oncology, autoimmune disorders, and infectious diseases. The company is known for its robust global pipeline and commercial operations in China, aiming to deliver first-in-class and best-in-class treatments.
Average Trading Volume: 14,692,157
Technical Sentiment Signal: Sell
Current Market Cap: HK$23B
Learn more about 9688 stock on TipRanks’ Stock Analysis page.